人工肝支持系统对肝衰竭患者免疫调节作用的研究进展

doi:10.3969/j.issn.1671-2587.2025.04.021

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (4): 571-576.DOI: 10.3969/j.issn.1671-2587.2025.04.021

• 综述 • 上一篇

人工肝支持系统对肝衰竭患者免疫调节作用的研究进展

朱鑫方, 孙菲, 钟瑶, 夏荣

复旦大学附属华山医院输血科,上海 200040

收稿日期:2024-11-29 出版日期:2025-08-20 发布日期:2025-08-22
通讯作者: 夏荣,主要从事输血相关免疫研究,（E-mail）xiarongcn@126.com。
作者简介:朱鑫方,主要从事血液单采治疗及相关研究,（E-mail）279676540@qq.com。

Advances in Immunoregulation of Artificial Liver Support System for Patients with Liver Failure

ZHU Xinfang, SUN Fei, ZHONG Yao, XIA Rong

Department of Transfusion, Huashan Hospital, Fudan University, Shanghai 200040

Received:2024-11-29 Online:2025-08-20 Published:2025-08-22

摘要/Abstract

摘要： 人工肝支持系统是肝衰竭患者治疗过程中重要的方法,可用于肝衰竭疾病进程的任何阶段。由于肝衰竭患者病程进展时常伴随严重的免疫功能紊乱,人工肝支持系统在进行改善功能、纠正凝血功能的同时,可能同时对患者的免疫功能进行调节,如淋巴细胞和单核巨噬细胞的调节等。本文从肝衰竭患者的免疫功能变化、人工肝支持系统的工作原理以及对免疫系统的调节等方面进行了回顾性分析,为将来人工肝支持系统的发展提供研究方向。

关键词: 人工肝支持系统, 肝衰竭, 免疫调节

Abstract: The artificial liver support system constitutes a critical intervention in the therapeutic management of patients experiencing liver failure and is applicable at any stage of the disease progression. Given that the trajectory of liver failure is frequently associated with significant immune dysfunction, the artificial support system not only enhances hepatic function and improves coagulation disorders but may also concurrently modulate the patient's immune response. This modulation includes the regulation of lymphocytes and mononuclear macrophages. We conducted a retrospective analysis of various aspects, including alterations in immune function among patients with liver failure, the operational mechanisms of the artificial liver support system, and the modulation of the immune system. The findings offer a prospective research trajectory for the advancement of artificial liver support systems.

Key words: Artificial liver support system, Liver failure, Immunoregulation

中图分类号:

R575.3

朱鑫方, 孙菲, 钟瑶, 夏荣. 人工肝支持系统对肝衰竭患者免疫调节作用的研究进展[J]. 临床输血与检验, 2025, 27(4): 571-576.

ZHU Xinfang, SUN Fei, ZHONG Yao, XIA Rong. Advances in Immunoregulation of Artificial Liver Support System for Patients with Liver Failure[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 571-576.

参考文献

[1] MAIWALL R,KULKARNI A V,ARAB J P,et al.Acute liver failure[J]. Lancet,2024,404(10454):789-802.
[2] 束越, 黄玫, 蔡伟,等. 肝细胞癌肝切除术后肝衰竭发生的危险因素分析及预测模型构建[J]. 中华消化外科杂志, 2023, 22(4): 505-511.
[3] LUYENDYK J P,MOROZOVA E,COPPLE B L.Good cells go bad:immune dysregulation in the transition from acute liver injury to liver failure after acetaminophen overdose[J]. Drug Metab Dispos,2024,52(8):722-728.
[4] ARROYO V,ANGELI P,MOREAU R,et al.The systemic inflammation hypothesis:Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J].J Hepatol,2021,74(3):670-685.
[5] SOLÉ C,SOLÀ E,HUELIN P,et al.Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival[J]. Liver Int,2019,39(7):1246-1255.
[6] FABRIS L,SPIRLI C,MERTENS J.Cell interactions in biliary diseases:clues from pathophysiology and repair mechanisms to foster early assessment[J]. Int J Mol Sci, 2019,20(16):3961.
[7] LARSEN F S,SALIBA F.Liver support systems and liver transplantation in acute liver failure[J]. Liver Int, 2025,45(3):e15633.
[8] RELA M,RAMMOHAN A.Why are there so many liver transplants from living donors in Asia and so few in Europe and the US?[J]. J Hepatol,2021,75(4):975-980.
[9] BAÑARES R,CATALINA M V,VAQUERO J. Molecular adsorbent recirculating system and bioartificial devices for liver failure[J]. Clin Liver Dis,2014,18(4):945-956.
[10] SALIBA F,BAÑARES R,LARSEN F S,et al. Artificial liver support in patients with liver failure:a modified DELPHI consensus of international experts[J]. Intensive Care Med,2022,48(10):1352-1367.
[11] FUJII Y,HIGASHI K,MIZUMOTO H,et al.A bioartificial liver device based on three-dimensional culture of genetically engineered hepatoma cells using hollow fibers[J]. Cytotechnology,2020,72(2):227-237.
[12] LEE J S,YOON H,YOON D,et al.Development of hepatic blocks using human adipose tissue-derived stem cells through three-dimensional cell printing techniques[J]. J Mater Chem B,2017,5(5):1098-1107.
[13] LEE K C L,BAKER L A,STANZANI G,et al. Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study[J]. J Hepatol,2015, 63(3): 634-642.
[14] SHEN Y,WANG X L,WANG B,et al.Survival benefits with artificial liver support system for acute-on-chronic liver failure:a time series-based meta-analysis[J]. Medicine (Baltimore),2016,95(3):e2506.
[15] YANG L L,WU T Z,LI J,et al.Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure:a case-control matched analysis[J]. Hepatol Res,2020,50(6):656-670.
[16] SITHAMPARAPILLAI K,ZACHARIAH U,EAPEN C E,et al.Plasma exchange improves survival in acute liver failure-An updated systematic review and meta-analysis focussed on comparing within single etiology[J]. Indian J Gastroenterol,2024,43(2):397-406.
[17] 中华医学会器官移植学分会围手术期管理学组. 肝衰竭肝移植围手术期管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(8): 835-840.
[18] WAN Y M,YANG L H,YANG J H,et al.The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure[J]. Hepatol Int,2016,10(3):462-469.
[19] MAIWALL R,BAJPAI M,SINGH A,et al.Standard-volume plasma exchange improves outcomes in patients with acute liver failure:a randomized controlled trial[J]. Clin Gastroenterol Hepatol,2022,20(4): e831-e854.
[20] MARTIROSYAN A,PETREK M,KISHORE A,et al.Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome[J].Exp Ther Med,2016,12(2):1189-1195.
[21] JIANG Y T,TIAN X,GU Y X,et al.Application of plasma exchange in steroid-responsive encephalopathy[J]. Front Immunol,2019,10:324.
[22] LI P,LIANG X,XU S,et al.A non-bioartificial liver support system combined with transplantation in HBV-related acute-on-chronic liver failure[J]. Sci Rep,2021, 11(1):2975.
[23] TANG L,WANG X,ZHAO R,et al.Yi-Qi-Jian-Pi formula ameliorates immune function in acute-on-chronic liver failure by upregulating autophagy and mitochondrial biogenesis in CD8+ T lymphocytes[J]. J Ethnopharmacol, 2023,308:116276.
[24] SELLAU J,PUENGEL T,HOENOW S,et al.Monocyte dysregulation:consequences for hepatic infections[J]. Semin Immunopathol,2021,43(4):493-506.
[25] MAO W L,LOU Y F,YE B,et al.Changes in peripheral CD4+ CD25 (high) regulatory T cells in the acute-on-chronic liver failure patients with plasma exchange treatment[J]. Inflammation,2012,35(2):436-444.
[26] HAKEEM A R,SANDEEP J,SUBRAMANIAM S,et al.Therapeutic plasma exchange for management of early allograft dysfunction after living donor liver transplant: an unmatched cohort study[J]. Exp Clin Transplant, 2021,19(11):1182-1190.
[27] 刘业,毛家玺,刘聪,等. 乙肝相关性慢加急性肝衰竭患者在肝移植等待期接受血浆置换的疗效分析[J]. 临床输血与检验, 2022, 24(1): 52-57.
[28] MAITTA R W,CHOATE J,EMRE S H,et al.Emergency ABO-incompatible liver transplant secondary to fulminant hepatic failure:outcome,role of TPE and review of the literature[J]. J Clin Apher,2012,27(6): 320-329.
[29] YANG Q,SHI Y,HE J L,et al.The evolving story of macrophages in acute liver failure[J]. Immunol Lett, 2012,147(1/2):1-9.
[30] WESTON C J,ZIMMERMANN H W,ADAMS D H.The role of myeloid-derived cells in the progression of liver disease[J]. Front Immunol,2019,10:893.
[31] VAN DER HEIDE D,WEISKIRCHEN R,BANSAL R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases[J]. Front Immunol,2019,10: 2852.
[32] FAN B,XIE H,TAN Q,et al.Role of exosomal modulation of macrophages in liver fibrosis[J]. J Clin Transl Hepatol, 2024,12(2):201-209.
[33] PEI L H,LE Y F,CHEN H,et al.Cynaroside prevents macrophage polarization into pro-inflammatory phenotype and alleviates cecal ligation and puncture-induced liver injury by targeting PKM2/HIF-1α axis[J]. Fitoterapia,2021,152:104922.
[34] BINATTI E,GERUSSI A,BARISANI D,et al.The role of macrophages in liver fibrosis:new therapeutic opportunities[J]. Int J Mol Sci,2022,23(12):6649.
[35] LI Y W,SHENG Q J,ZHANG C,et al.STAT6 up-regulation amplifies M2 macrophage anti-inflammatory capacity through mesenchymal stem cells[J]. Int Immunopharmacol,2021,91:107266.
[36] POSSAMAI L A,THURSZ M R,WENDON J A, et al.Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure[J]. J Hepatol,2014,61(2):439-445.
[37] PIREAUX V,DELPORTE C,ROUSSEAU A,et al.M2 monocyte polarization in dialyzed patients is associated with increased levels of M-CSF and myeloperoxidase-associated oxidative stress:preliminary results[J]. Biomedicines,2021,9(1):84.
[38] XU W X,HE H L,PAN S W,et al.Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with hepatitis B virus-related acute-on-chronic liver failure:a clinical trial in China[J]. Stem Cells Int, 2019,2019:4130757.
[39] ZHENG Y Y,ZHU S,ZHENG X R,et al.Serum from acute-on-chronic liver failure patients may affect mesenchymal stem cells transplantation by impairing the immunosuppressive function of cells[J]. J Clin Transl Hepatol,2021,9(4):503-513.
[40] SCHARF C,LIEBCHEN U,PAAL M,et al.Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis:a pilot study[J]. Sci Rep,2021,11(1): 10190.
[41] PFENSIG C,DOMINIK A,BORUFKA L,et al.A new application for albumin dialysis in extracorporeal organ support:characterization of a putative interaction between human albumin and proinflammatory cytokines IL-6 and TNFα[J]. Artif Organs,2016,40(4):397-402.
[42] WEISS E,DE LA GRANGE P,DEFAYE M,et al. Characterization of blood immune cells in patients with decompensated cirrhosis including ACLF[J]. Front Immunol,2021,11:619039.
[43] VAN H B.Defining the value of extracorporeal liver support in acute and acute-on-chronic liver failure[J]. J Clin Transl Hepatol,2023,11(3):517-520.
[44] WANG L,XU W X,ZHU S,et al.Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure:a prospective study[J]. J Clin Transl Hepatol,2023,11(4):908-917.
[45] SHINGINA A,MUKHTAR N,WAKIM-FLEMING J, et al.Acute liver failure guidelines[J]. Am J Gastroenterol, 2023,118(7):1128-1153.
[46] FELGENDREFF P,THARWAT M,HOSSEINIASL S M, et al.Preclinical experience of the mayo spheroid reservoir bioartificial liver (SRBAL) in management of acute liver failure[J]. Livers,2022,2(4):387-399.
[47] BRAM Y,NGUYEN D T,GUPTA V,et al.Cell and tissue therapy for the treatment of chronic liver disease[J]. Annu Rev Biomed Eng,2021,23:517-546.
[48] LIU J F,YUAN Z M,WANG Q W.Pluripotent stem cell-derived strategies to treat acute liver failure:current status and future directions[J]. J Clin Transl Hepatol, 2022,10(4):692-699.
[49] JAIN S,SHARMA J G.Unconventional strategies for liver tissue engineering:plant,paper,silk and nanomaterial-based scaffolds[J]. Regen Med,2024, 19(7/8):421-437.
[50] UYGUN B E,IZAMIS M L,JARAMILLO M,et al.Discarded livers find a new life:engineered liver grafts using hepatocytes recovered from marginal livers[J]. Artif Organs,2017,41(6):579-585.
[51] LI W J,ZHU X J,YUAN T J,et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs[J]. Sci Transl Med,2020,12(551):eaba5146.
[52] TUERXUN K,HE J Y,IBRAHIM I,et al.Bioartificial livers:a review of their design and manufacture[J]. Biofabrication,2022,14(3).
[53] XUE W S,ZHANG H J,KE J J,et al.A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs[J]. Hepatobiliary Pancreat Dis Int,2023,22(3):270-281.
[54] SHI S,YANG Y F,LIU Y L,et al.Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system[J]. Front Med (Lausanne),2024,11:1368899.

人工肝支持系统对肝衰竭患者免疫调节作用的研究进展

Advances in Immunoregulation of Artificial Liver Support System for Patients with Liver Failure

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	庄远, 于洋. 输血（医学）科基于离心分离技术建立单采/血液净化治疗体系的探索[J]. 临床输血与检验, 2024, 26(6): 721-725.
[2]	李佩华, 苏焕正, 沙夏珺, 罗文英. 慢加急性肝衰竭血浆置换治疗期间死亡的危险因素探讨：基于PSM法[J]. 临床输血与检验, 2024, 26(3): 345-352.
[3]	朱自严. 红细胞血型抗原的同种免疫[J]. 临床输血与检验, 2022, 24(1): 1-6.
[4]	刘业, 毛家玺, 刘聪, 宋晨梦, 陈蕾宇, 郭闻渊, 滕飞, 唐晓峰. 乙肝相关性慢加急性肝衰竭患者在肝移植等待期接受血浆置换的疗效分析*[J]. 临床输血与检验, 2022, 24(1): 52-57.
[5]	张淑琼, 江贤, 保凌, 杨瑾, 汤浦娟. Rh（D）阴性慢性乙肝患者二胎妊娠致肝衰竭紧急抢救1例[J]. 临床输血与检验, 2019, 21(1): 100-101.